pubmed-article:20412855 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C0175677 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C0022646 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C0039198 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C2004454 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C0332208 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C0209368 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C1416467 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C0599896 | lld:lifeskim |
pubmed-article:20412855 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
pubmed-article:20412855 | pubmed:issue | 1-2 | lld:pubmed |
pubmed-article:20412855 | pubmed:dateCreated | 2010-6-28 | lld:pubmed |
pubmed-article:20412855 | pubmed:abstractText | Lymphocytes participate in the early pathogenesis of ischemia-reperfusion injury (IRI) in kidney; however, their role during repair is largely unknown. Recent data have shown that Foxp3(+) regulatory T cells (Tregs) traffic into kidney during healing from IRI and directly participate in repair. Since lymphocyte-targeting therapy is currently administered to prevent rejection during recovery from IRI in renal transplants, we hypothesized that mycophenolate mofetil (MMF) would alter Treg trafficking and kidney repair. C57BL/6J and T cell deficient mice underwent unilateral clamping of renal pedicle for 45 min, followed by reperfusion, and were sacrificed at day 10. Mice were treated with saline (C) or MMF (100mg/kg) i.p. daily starting at day 2 until sacrifice (n=5-12/group). MMF worsened kidney tubular damage compared to C at 10 days (cortex and outer medulla: p<0.05) in wild-type mice; tubular apoptotic index was increased in cortex in MMF group as well (p=0.01). MMF reduced the total number of kidney-infiltrating mononuclear cells (p<0.001 versus C) and the percentages of TCRbeta(+)CD4(+) and TCRbeta(+)CD8(+) T cells (p<0.01), but not natural killer (NK), NKT or B lymphocytes. MMF specifically reduced kidney Foxp3(+) Tregs (0.82+/-0.11% versus 1.75+/-0.17%, p<0.05). Tubular proliferative index and tissue levels of basic FGF were increased in MMF group (p<0.05), IL-10 and IL-6 were decreased (p<0.05). To evaluate if MMF effect occurred through non-lymphocytic cells, T cell deficient mice were treated with MMF. Tubular injury in T cell deficient mice was not affected by MMF treatment, though MMF-treated animals had increased VEGF and decreased PDGF-BB protein tissue levels compared to controls (p<0.05). Thus, MMF modifies the structural, epithelial proliferative and inflammatory response during healing, likely through effects on T cells and possibly Tregs. Kidney repair after IRI can be altered by agents that target lymphocytes. | lld:pubmed |
pubmed-article:20412855 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:language | eng | lld:pubmed |
pubmed-article:20412855 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20412855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20412855 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20412855 | pubmed:month | May | lld:pubmed |
pubmed-article:20412855 | pubmed:issn | 1878-5492 | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:CrowMichael... | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:RabbHamidH | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:BagnascoSeren... | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:GandolfoMaria... | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:SoloskiMark... | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:KoGang-JeeGJ | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:JangHye... | lld:pubmed |
pubmed-article:20412855 | pubmed:author | pubmed-author:AgredaPatrici... | lld:pubmed |
pubmed-article:20412855 | pubmed:copyrightInfo | Copyright (c) 2010 Elsevier B.V. All rights reserved. | lld:pubmed |
pubmed-article:20412855 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20412855 | pubmed:volume | 23 | lld:pubmed |
pubmed-article:20412855 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20412855 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20412855 | pubmed:pagination | 45-52 | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:meshHeading | pubmed-meshheading:20412855... | lld:pubmed |
pubmed-article:20412855 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20412855 | pubmed:articleTitle | Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion. | lld:pubmed |
pubmed-article:20412855 | pubmed:affiliation | Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA. | lld:pubmed |
pubmed-article:20412855 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:20412855 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |